Page 10 - Cholangiocarcinoma Intrahepatic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cholangiocarcinoma intrahepatic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cholangiocarcinoma Intrahepatic Today - Breaking & Trending Today

A Deep Hole: The Cancer Cost Toll Patients and Families Face

Patients and their families share the financial hardships they experience trying to stay afloat after a cancer diagnosis. ....

New York , United States , South Carolina , Memorial Sloan Kettering Cancer Center , Ann Arbor , New Jersey , Brittany Dicks , Molly Macdonald , Joshua Palmer , Stephanie Caputo , Ali Smith , Fumiko Chino , Danielle Hadfield , University Of Texas Md Anderson Cancer Center , Pink Fund , University Of Michigan , Grace Li Smith , Cancer Center , Washington State , New York State , For Caputo , Breast Cancer , Alignant Breast Neoplasm , Alignant Neoplasia , Health Care Economics , Health Insurance ,

"Combination chemotherapy with NAB<sup>®</sup>-paclitaxel and capecitab" by Rachel Woodford, Daniel Brungs et al.

Background: Advanced biliary tract cancer (ABTC) is a highly aggressive malignancy, with a 5-year overall survival of < 10%. Although preliminary evidence suggests a role of targeted treatments or immunotherapy in a subset of patients, chemotherapy remains the standard second-line treatment in the majority. We conducted a pilot study of second-line chemotherapy with capecitabine and nab-paclitaxel after failure of gemcitabine and platinum. Methods: Eligible patients had histologically proven, unresectable biliary tract cancer, which had progressed on a gemcitabine/platinum doublet. In this single-arm, multicenter trial, all patients received capecitabine (825 mg/m2 bd PO D1-14 q21d) and nab-paclitaxel (125 mg/m2 IV D1,8 q21d) until progression or unacceptable toxicity. The primary objective was feasibility of delivering the proposed regimen, with secondary objectives of disease control measures and QOL outcomes. Results: Ten patients were enrolled between 2015 and 2016 from four can ....

Advanced Biliary Tract Cancer , Second Line Treatment ,

FDA approves Taiho drug for rare bile duct cancer with certain genetic signature

Taiho Oncology’s cancer drug Lytgobi is the third FDA-approved therapy for bile duct cancer driven by FGFR2 genetic alterations. The accelerated approval for Taiho’s drug follows regulatory nods for products from Incyte and QED Therapeutics that address the same genetic signature. ....

United States , Hong Kong , Bio Pharma , Incyte Pemazyre , Helsinn Group , Otsuka Holdings , American Cancer Society , Taiho Oncology , American Cancer , Switzerland Based Helsinn Group , New Jersey Based Taiho Oncology , Taiho Pharmaceutical , Tokyo Based Otsuka Holdings , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It ,

FDA Approves Futibatinib for Certain Biliary Tract Cancers

The indication is for use in adult patients with previously treated intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. ....

United States , Lipika Goyal , Hospital Cancer Center , Drug Administration , Massachusetts General Hospital Cancer Center , Hepatocellular Carcinoma , Liver Cancer , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Us Food And Drug Administration , Nited States Food And Drug Administration , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Abdominal Pain , Alignant Neoplasia , Pain Management , Pain Management ,

Taiho Oncology, Inc.: FDA Approves Taiho's LYTGOBI (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

LYTGOBI (pronounced "light-GOH-bee") delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI ....

United States , New Jersey , Kostenloser Wertpapierhandel , Teruhiro Utsugi , Lipika Goyal , Judy Kay Moore , Gastroenterol Hepatol , Tim Whitten , Taiho Pharmaceutical Co Ltd , Hospital Cancer Center , Drug Administration , Janssen Pharmaceutical Companies , Taiho Oncology Inc , Prnewswire Taiho Oncology Inc , Otsuka Holdings Co Ltd , Incyte Corporation , American Cancer Society , Taiho Oncology , Massachusetts General Hospital Cancer Center , Taiho Pharmaceutical , Senior Managing Director , Pigment Epithelial Detachment , Corneal Keratitis , Soft Tissue Mineralization , Prescribing Information , Oncology Media Contact ,